WBB Securities Upgrades Turn Therapeutics (NASDAQ:TTRX) to "Hold"

Turn Therapeutics (NASDAQ:TTRX - Get Free Report) was upgraded by investment analysts at WBB Securities from a "sell" rating to a "hold" rating in a report released on Friday, Marketbeat.com reports. The firm currently has a $10.00 target price on the stock. WBB Securities's price objective suggests a potential downside of 4.03% from the company's current price.

TTRX has been the topic of several other research reports. Weiss Ratings lowered shares of Turn Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, August 18th. Lucid Cap Mkts upgraded shares of Turn Therapeutics to a "strong-buy" rating in a research note on Thursday, September 24th. Zacks Research upgraded shares of Turn Therapeutics to a "hold" rating in a research note on Tuesday, July 21st. LADENBURG THALM/SH SH upgraded shares of Turn Therapeutics to a "strong-buy" rating in a research note on Monday, July 20th. Finally, Wall Street Zen downgraded shares of Turn Therapeutics from a "hold" rating to a "sell" rating in a research note on Sunday, October 18th. Two research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $9.00.

Turn Therapeutics Price Performance

NASDAQ:TTRX traded down $0.19 during midday trading on Friday, hitting $10.42. 98,415 shares of the stock were exchanged, compared to its average volume of 67,290. Turn Therapeutics has a one year low of $2.57 and a one year high of $16.45. The company has a market capitalization of $318.12 million and a price-to-earnings ratio of -35.93. The business has a 50-day moving average price of $11.64 and a two-hundred day moving average price of $6.86. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 8.83.

Turn Therapeutics (NASDAQ:TTRX - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter. Sell-side analysts predict that Turn Therapeutics will post -0.40 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in TTRX. TD Waterhouse Canada Inc. acquired a new position in Turn Therapeutics in the third quarter worth about $40,000. Bank of America Corp DE acquired a new position in Turn Therapeutics in the second quarter worth about $103,000. Jefferies Financial Group Inc. acquired a new position in Turn Therapeutics in the second quarter worth about $119,000. DDFG Inc raised its position in Turn Therapeutics by 34.9% in the first quarter. DDFG Inc now owns 70,534 shares of the company's stock worth $226,000 after purchasing an additional 18,246 shares in the last quarter. Finally, Bridgewater Advisors Inc. acquired a new position in Turn Therapeutics in the second quarter worth about $242,000.

About Turn Therapeutics

Turn Therapeutics, Inc is a biotechnology and pharmaceutical company focused on developing topical therapies for skin and wound-care applications. The company's platform is designed to support the delivery of therapeutic compounds to the skin while helping address microbial contamination and other complications associated with wounds.

Turn Therapeutics has identified MVT-100 as a lead product candidate. The topical formulation is intended for use in wound-care settings, including the management of chronic and difficult-to-heal wounds.